BHC-C: Registry of Multicenter Brain-Heart Comorbidity in China
Study Details
Study Description
Brief Summary
This study is a multi-center, prospective, registry study. This research was supported by the National Key Research and Development Program. To establish a domestic multi-center, large-scale "brain-heart comorbidity" dynamic database platform including clinical, sample database, image and other multi-dimensional information requirements, through the construction of a multi-center intelligent scientific research integration platform based on artificial intelligence.
Any of newly diagnosed cardiovascular related diseases were identified via ICD-10-CM codes:
I21, I22, I24 (Ischaemic heart diseases) [i.e., ACS], I46 (cardiac arrest), I48 (Atrial fibrillation/flutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).
The data is stored on the brain-heart comorbidity warehouse via a physical server at the institution's data centre or a virtual hosted appliance. The brain-heart comorbidity platform comprises of a series of these appliances connected into a multicenter network. This network can broadcast queries to each appliance. Results are subsequently collected and aggregated. Once the data is sent to the network, it is mapped to a standard and controlled set of clinical terminologies and undergoes a data quality assessment including 'data cleaning' that rejects records which do not meet the brain-heart comorbidity quality standards. The brain-heart comorbidity warehouse performs internal and extensive data quality assessment with every refresh based on conformance, completeness, and plausibility (http://10.100.101.65:30080/login).
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Rate of Participants with Composite of All-Cause Mortality and Cardiovascular Outcomes [At discharge/30 days]
The occurrence of all-cause mortality, coronary artery disease event, stroke (ischemic or hemorrhagic), heart failure, or atrial fibrillation etc.
- All-Cause Mortality [At discharge/30 days]
The occurrence of death
- Rate of Participants with Composite of Cardiovascular Outcomes [At discharge/30 days]
The occurrence of coronary artery disease event, stroke (ischemic or hemorrhagic), heart failure, or atrial fibrillation etc.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
age > 18 years old
-
Any of newly diagnosed cardiovascular-related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) [i.e., ACS], I46 (cardiac arrest), I48 (Atrial fibrillation/flutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).
Exclusion Criteria:
·refuse to participate in the registry
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Beijing Tiantan Hospital, Capital Medical University | Beijing | Beijing | China | 100070 |
2 | Beijing Anzhen Hospital, Capital Medical University | Beijing | Beijing | China | |
3 | Beijing Chaoyang Hospital, Capital Medical University | Beijing | Beijing | China | |
4 | Chinese People's Liberation Army (PLA) General Hospital | Beijing | Beijing | China | |
5 | Peking University First Hospital | Beijing | Beijing | China | |
6 | Xuanwu Hospital, Capital Medical University | Beijing | Beijing | China | |
7 | The First Affiliated Hospital of Fujian Medical University | Fuzhou | Fujian | China | |
8 | The First Affiliated Hospital of Xiamen University | Xiamen | Fujian | China | |
9 | Shenzhen Qianhai Shekou Free Trade Zone Hospital | Shenzhen | Guangdong | China | |
10 | The First Affiliated Hospital of Harbin Medical University | Harbin | Heilongjiang | China | |
11 | The First Affiliated Hospital of Zhengzhou University | Zhengzhou | Henan | China | |
12 | Huashan Hospital of Fudan University | Shanghai | Shanghai | China | |
13 | Shanxi Provincial People's Hospital | Shanxi | Shanxi | China | |
14 | The Second Affiliated Hospital of Kunming Medical University | Kunming | Yunnan | China |
Sponsors and Collaborators
- Beijing Tiantan Hospital
Investigators
- Study Chair: Shuo Wang, MD, Beijing Tiantan Hospital
- Study Director: Yong Cao, MD, Beijing Tiantan Hospital
- Principal Investigator: Dong Xu, MD, Beijing Tiantan Hospital
- Principal Investigator: Zening Jin, MD, Beijing Tiantan Hospital
- Principal Investigator: Hao Wang, MD, Beijing Tiantan Hospital
- Principal Investigator: Shaui Kang, MD, Beijing Tiantan Hospital
- Principal Investigator: Yu Chen, MD, Beijing Tiantan Hospital
- Principal Investigator: Qingyuan Liu, MD, Beijing Tiantan Hospital
- Principal Investigator: Runting Li, MD, Beijing Tiantan Hospital
- Principal Investigator: Heze Han, MD, Beijing Tiantan Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- KY2022-221-02